Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges.

Saenz-Antoñanzas A, Auzmendi-Iriarte J, Carrasco-Garcia E, Moreno-Cugnon L, Ruiz I, Villanua J, Egaña L, Otaegui D, Samprón N, Matheu A.

Cancers (Basel). 2019 Jul 5;11(7). pii: E950. doi: 10.3390/cancers11070950. Review.

2.

The circulating transcriptome as a source of cancer liquid biopsy biomarkers.

Sole C, Arnaiz E, Manterola L, Otaegui D, Lawrie CH.

Semin Cancer Biol. 2019 Jan 23. pii: S1044-579X(18)30100-7. doi: 10.1016/j.semcancer.2019.01.003. [Epub ahead of print] Review.

PMID:
30684535
3.

CircRNAs and cancer: Biomarkers and master regulators.

Arnaiz E, Sole C, Manterola L, Iparraguirre L, Otaegui D, Lawrie CH.

Semin Cancer Biol. 2018 Dec 11. pii: S1044-579X(18)30099-3. doi: 10.1016/j.semcancer.2018.12.002. [Epub ahead of print] Review.

PMID:
30550956
4.

Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloidβ Are Strongly Associated With Healthy Aging in the Oldest Old.

Fernández-Eulate G, Alberro A, Muñoz-Culla M, Zulaica M, Zufiría M, Barandiarán M, Etxeberria I, Yanguas JJ, Gallardo MM, Soberón N, Lacosta AM, Pérez-Grijalba V, Canudas J, Fandos N, Pesini P, Sarasa M, Indakoetxea B, Moreno F, Vergara I, Otaegui D, Blasco M, López de Munain A.

Front Aging Neurosci. 2018 Nov 28;10:380. doi: 10.3389/fnagi.2018.00380. eCollection 2018.

5.

Therapeutic Potential of Extracellular Vesicles for Demyelinating Diseases; Challenges and Opportunities.

Osorio-Querejeta I, Alberro A, Muñoz-Culla M, Mäger I, Otaegui D.

Front Mol Neurosci. 2018 Nov 23;11:434. doi: 10.3389/fnmol.2018.00434. eCollection 2018. Review.

6.

The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients.

Sáenz-Cuesta M, Alberro A, Muñoz-Culla M, Osorio-Querejeta I, Fernandez-Mercado M, Lopetegui I, Tainta M, Prada Á, Castillo-Triviño T, Falcón-Pérez JM, Olascoaga J, Otaegui D.

Int J Mol Sci. 2018 Aug 19;19(8). pii: E2448. doi: 10.3390/ijms19082448.

7.

In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.

Pérez-Salvia M, Aldaba E, Vara Y, Fabre M, Ferrer C, Masdeu C, Zubia A, Sebastian ES, Otaegui D, Llinàs-Arias P, Rosselló-Tortella M, Berdasco M, Moutinho C, Setien F, Villanueva A, González-Barca E, Muncunill J, Navarro JT, Piris MA, Cossio FP, Esteller M.

Haematologica. 2018 Nov;103(11):e537-e540. doi: 10.3324/haematol.2018.189241. Epub 2018 Jun 7. No abstract available.

8.

Expression Profiling Analysis Reveals Key MicroRNA-mRNA Interactions in Early Retinal Degeneration in Retinitis Pigmentosa.

Anasagasti A, Ezquerra-Inchausti M, Barandika O, Muñoz-Culla M, Caffarel MM, Otaegui D, López de Munain A, Ruiz-Ederra J.

Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2381-2392. doi: 10.1167/iovs.18-24091.

9.

Transcriptomic integration of D4R and MOR signaling in the rat caudate putamen.

Valderrama-Carvajal A, Irizar H, Gago B, Jiménez-Urbieta H, Fuxe K, Rodríguez-Oroz MC, Otaegui D, Rivera A.

Sci Rep. 2018 May 9;8(1):7337. doi: 10.1038/s41598-018-25604-4.

10.

Circular RNA profiling reveals that circular RNAs from ANXA2 can be used as new biomarkers for multiple sclerosis.

Iparraguirre L, Muñoz-Culla M, Prada-Luengo I, Castillo-Triviño T, Olascoaga J, Otaegui D.

Hum Mol Genet. 2017 Sep 15;26(18):3564-3572. doi: 10.1093/hmg/ddx243.

PMID:
28651352
11.

Models for Studying Myelination, Demyelination and Remyelination.

Osorio-Querejeta I, Sáenz-Cuesta M, Muñoz-Culla M, Otaegui D.

Neuromolecular Med. 2017 Sep;19(2-3):181-192. doi: 10.1007/s12017-017-8442-1. Epub 2017 May 23. Review.

PMID:
28536996
12.

Progressive changes in non-coding RNA profile in leucocytes with age.

Muñoz-Culla M, Irizar H, Gorostidi A, Alberro A, Osorio-Querejeta I, Ruiz-Martínez J, Olascoaga J, López de Munain A, Otaegui D.

Aging (Albany NY). 2017 Apr;9(4):1202-1218. doi: 10.18632/aging.101220.

13.

Yerba mate (Ilex paraguariensis) inhibits lymphocyte activation in vitro.

Muñoz-Culla M, Sáenz-Cuesta M, Guereca-Barandiaran MJ, Ribeiro ML, Otaegui D.

Food Funct. 2016 Nov 9;7(11):4556-4563.

PMID:
27714004
14.

Cancer risk in DM1 is sex-related and linked to miRNA-200/141 downregulation.

Fernández-Torrón R, García-Puga M, Emparanza JI, Maneiro M, Cobo AM, Poza JJ, Espinal JB, Zulaica M, Ruiz I, Martorell L, Otaegui D, Matheu A, López de Munain A.

Neurology. 2016 Sep 20;87(12):1250-7. doi: 10.1212/WNL.0000000000003124. Epub 2016 Aug 24.

PMID:
27558368
15.

Inflammaging and Frailty Status Do Not Result in an Increased Extracellular Vesicle Concentration in Circulation.

Alberro A, Sáenz-Cuesta M, Muñoz-Culla M, Mateo-Abad M, Gonzalez E, Carrasco-Garcia E, Araúzo-Bravo MJ, Matheu A, Vergara I, Otaegui D.

Int J Mol Sci. 2016 Jul 20;17(7). pii: E1168. doi: 10.3390/ijms17071168.

16.

Ferritin-mediated siRNA delivery and gene silencing in human tumor and primary cells.

Li L, Muñoz-Culla M, Carmona U, Lopez MP, Yang F, Trigueros C, Otaegui D, Zhang L, Knez M.

Biomaterials. 2016 Aug;98:143-51. doi: 10.1016/j.biomaterials.2016.05.006. Epub 2016 May 5.

PMID:
27187278
17.

SncRNA (microRNA &snoRNA) opposite expression pattern found in multiple sclerosis relapse and remission is sex dependent.

Muñoz-Culla M, Irizar H, Sáenz-Cuesta M, Castillo-Triviño T, Osorio-Querejeta I, Sepúlveda L, López de Munain A, Olascoaga J, Otaegui D.

Sci Rep. 2016 Feb 1;6:20126. doi: 10.1038/srep20126.

18.

Age gene expression and coexpression progressive signatures in peripheral blood leukocytes.

Irizar H, Goñi J, Alzualde A, Castillo-Triviño T, Olascoaga J, Lopez de Munain A, Otaegui D.

Exp Gerontol. 2015 Dec;72:50-6. doi: 10.1016/j.exger.2015.09.003. Epub 2015 Sep 8.

PMID:
26362218
19.

Editorial: Novel Clinical Applications of Extracellular Vesicles.

Sáenz-Cuesta M, Mittelbrunn M, Otaegui D.

Front Immunol. 2015 Jul 24;6:381. doi: 10.3389/fimmu.2015.00381. eCollection 2015. No abstract available.

20.

A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis.

Matesanz F, Potenciano V, Fedetz M, Ramos-Mozo P, Abad-Grau Mdel M, Karaky M, Barrionuevo C, Izquierdo G, Ruiz-Peña JL, García-Sánchez MI, Lucas M, Fernández Ó, Leyva L, Otaegui D, Muñoz-Culla M, Olascoaga J, Vandenbroeck K, Alloza I, Astobiza I, Antigüedad A, Villar LM, Álvarez-Cermeño JC, Malhotra S, Comabella M, Montalban X, Saiz A, Blanco Y, Arroyo R, Varadé J, Urcelay E, Alcina A.

Hum Mol Genet. 2015 Oct 1;24(19):5619-27. doi: 10.1093/hmg/ddv256. Epub 2015 Jul 7.

PMID:
26152201
21.

The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids.

Fernandez-Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M, Otaegui D, Lawrie CH.

J Cell Mol Med. 2015 Oct;19(10):2307-23. doi: 10.1111/jcmm.12625. Epub 2015 Jun 27. Review.

22.

Identification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA - mRNA network analysis.

Irizar H, Muñoz-Culla M, Sáenz-Cuesta M, Osorio-Querejeta I, Sepúlveda L, Castillo-Triviño T, Prada A, Lopez de Munain A, Olascoaga J, Otaegui D.

BMC Genomics. 2015 Mar 28;16:250. doi: 10.1186/s12864-015-1396-5.

23.

Methods for extracellular vesicles isolation in a hospital setting.

Sáenz-Cuesta M, Arbelaiz A, Oregi A, Irizar H, Osorio-Querejeta I, Muñoz-Culla M, Banales JM, Falcón-Pérez JM, Olascoaga J, Otaegui D.

Front Immunol. 2015 Feb 13;6:50. doi: 10.3389/fimmu.2015.00050. eCollection 2015.

24.

Development and validation of a LC-MS assay for the quantification of ikh12 a novel anti-tumor candidate in rat plasma and tissues and its application in a pharmacokinetic study.

Otaegui D, Masdeu C, Aldaba E, Vara Y, Zubia A, San Sebastian E, Alcalá M, Villafruela S, Cossío FP, Rodriguez-Gascón A.

Biomed Chromatogr. 2015 Aug;29(8):1249-58. doi: 10.1002/bmc.3414. Epub 2015 Jan 23.

PMID:
25616154
25.

Neurogenetic disorders in the Basque population.

Martí Massó JF, Zarranz JJ, Otaegui D, López de Munain A.

Ann Hum Genet. 2015 Jan;79(1):57-75. doi: 10.1111/ahg.12088. Epub 2014 Dec 1. Review.

26.

Neural-competent cells of adult human dermis belong to the Schwann lineage.

Etxaniz U, Pérez-San Vicente A, Gago-López N, García-Dominguez M, Iribar H, Aduriz A, Pérez-López V, Burgoa I, Irizar H, Muñoz-Culla M, Vallejo-Illarramendi A, Leis O, Matheu A, Martín AG, Otaegui D, López-Mato MP, Gutiérrez-Rivera A, MacLellan R, Izeta A.

Stem Cell Reports. 2014 Nov 11;3(5):774-88. doi: 10.1016/j.stemcr.2014.09.009. Epub 2014 Oct 16.

27.

Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis.

Sáenz-Cuesta M, Irizar H, Castillo-Triviño T, Muñoz-Culla M, Osorio-Querejeta I, Prada A, Sepúlveda L, López-Mato MP, López de Munain A, Comabella M, Villar LM, Olascoaga J, Otaegui D.

Biomark Med. 2014;8(5):653-61. doi: 10.2217/bmm.14.9.

PMID:
25123034
28.

Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.

Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, López de Munain A, Olascoaga J, Baranzini SE, Otaegui D.

Mult Scler. 2014 Dec;20(14):1851-9. doi: 10.1177/1352458514534513. Epub 2014 May 22.

PMID:
24852919
29.

Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us?

Sáenz-Cuesta M, Osorio-Querejeta I, Otaegui D.

Front Cell Neurosci. 2014 Mar 28;8:100. doi: 10.3389/fncel.2014.00100. eCollection 2014. Review.

30.

[Cognitive performance and quality of life in multiple sclerosis in Gipuzkoa].

Sistiaga A, Castillo-Triviño T, Aliri J, Gaztañaga M, Acha J, Arruti M, Otaegui D, Olascoaga J.

Rev Neurol. 2014 Apr 16;58(8):337-44. Spanish.

31.

Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression.

Irizar H, Muñoz-Culla M, Sepúlveda L, Sáenz-Cuesta M, Prada Á, Castillo-Triviño T, Zamora-López G, López de Munain A, Olascoaga J, Otaegui D.

PLoS One. 2014 Feb 28;9(2):e90482. doi: 10.1371/journal.pone.0090482. eCollection 2014.

32.

The genetics of multiple sclerosis: review of current and emerging candidates.

Muñoz-Culla M, Irizar H, Otaegui D.

Appl Clin Genet. 2013 Aug 8;6:63-73. doi: 10.2147/TACG.S29107. eCollection 2013. Review.

33.

Longitudinal clinical follow-up of a large family with the R357P Twinkle mutation.

Paradas C, Camaño P, Otaegui D, Oz O, Emmanuele V, DiMauro S, Hirano M.

JAMA Neurol. 2013 Nov;70(11):1425-8. doi: 10.1001/jamaneurol.2013.3185.

34.

Fine mapping and functional analysis of the multiple sclerosis risk gene CD6.

Swaminathan B, Cuapio A, Alloza I, Matesanz F, Alcina A, García-Barcina M, Fedetz M, Fernández O, Lucas M, Orpez T, Pinto-Medel MJ, Otaegui D, Olascoaga J, Urcelay E, Ortiz MA, Arroyo R, Oksenberg JR, Antigüedad A, Tolosa E, Vandenbroeck K.

PLoS One. 2013 Apr 24;8(4):e62376. doi: 10.1371/journal.pone.0062376. Print 2013.

35.

Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk.

Lill CM, Schjeide BM, Graetz C, Liu T, Damotte V, Akkad DA, Blaschke P, Gerdes LA, Kroner A, Luessi F, Cournu-Rebeix I, Hoffjan S, Winkelmann A, Touze E, Pico F, Corcia P, Otaegui D, Antigüedad A, Alcina A, Comabella M, Montalban X, Olascoaga J, Matesanz F, Dörner T, Li SC, Steinhagen-Thiessen E, Lindenberger U, Chan A, Rieckmann P, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Fontaine B, Zipp F, Vandenbroeck K, Bertram L.

J Med Genet. 2013 Mar;50(3):140-3. doi: 10.1136/jmedgenet-2012-101411. Epub 2013 Jan 12. No abstract available.

PMID:
23315543
36.

Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis.

Alcina A, Fedetz M, Fernández O, Saiz A, Izquierdo G, Lucas M, Leyva L, García-León JA, Abad-Grau Mdel M, Alloza I, Antigüedad A, Garcia-Barcina MJ, Vandenbroeck K, Varadé J, de la Hera B, Arroyo R, Comabella M, Montalban X, Petit-Marty N, Navarro A, Otaegui D, Olascoaga J, Blanco Y, Urcelay E, Matesanz F.

J Med Genet. 2013 Jan;50(1):25-33. doi: 10.1136/jmedgenet-2012-101085. Epub 2012 Nov 17.

37.

TACI mutation in Good's Syndrome: in search of a genetic basis.

Sáenz-Cuesta M, Martínez-Pomar N, de Gracia J, Echaniz P, Villegas E, Prada A, Otaegui D, Matamoros N, Cuadrado E.

Clin Immunol. 2012 Oct;145(1):27-30. doi: 10.1016/j.clim.2012.07.014. Epub 2012 Aug 4. No abstract available.

PMID:
22922270
38.

Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes.

Varadé J, Comabella M, Ortiz MA, Arroyo R, Fernández O, Pinto-Medel MJ, Fedetz M, Izquierdo G, Lucas M, Gómez CL, Rabasa AC, Alcina A, Matesanz F, Alloza I, Antigüedad A, García-Barcina M, Otaegui D, Olascoaga J, Saiz A, Blanco Y, Montalbán X, Vandenbroeck K, Urcelay E.

Mult Scler. 2012 Jul;18(7):959-65. doi: 10.1177/1352458511432741. Epub 2011 Dec 22.

PMID:
22194214
39.

Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis.

Cantó E, Reverter F, Morcillo-Suárez C, Matesanz F, Fernández O, Izquierdo G, Vandenbroeck K, Rodríguez-Antigüedad A, Urcelay E, Arroyo R, Otaegui D, Olascoaga J, Saiz A, Navarro A, Sanchez A, Domínguez C, Caminero A, Horga A, Tintoré M, Montalban X, Comabella M.

Mult Scler. 2012 Jul;18(7):983-90. doi: 10.1177/1352458511433063. Epub 2011 Dec 19.

PMID:
22183936
40.

ANKRD55 and DHCR7 are novel multiple sclerosis risk loci.

Alloza I, Otaegui D, de Lapuente AL, Antigüedad A, Varadé J, Núñez C, Arroyo R, Urcelay E, Fernandez O, Leyva L, Fedetz M, Izquierdo G, Lucas M, Oliver-Martos B, Alcina A, Saiz A, Blanco Y, Comabella M, Montalban X, Olascoaga J, Matesanz F, Vandenbroeck K.

Genes Immun. 2012 Apr;13(3):253-7. doi: 10.1038/gene.2011.81. Epub 2011 Dec 1.

PMID:
22130326
41.

HLA-DRB1*15:01 and multiple sclerosis: a female association?

Irizar H, Muñoz-Culla M, Zuriarrain O, Goyenechea E, Castillo-Triviño T, Prada A, Saenz-Cuesta M, De Juan D, Lopez de Munain A, Olascoaga J, Otaegui D.

Mult Scler. 2012 May;18(5):569-77. doi: 10.1177/1352458511426813. Epub 2011 Nov 29.

PMID:
22127897
42.

Replication of top markers of a genome-wide association study in multiple sclerosis in Spain.

Cavanillas ML, Fernández O, Comabella M, Alcina A, Fedetz M, Izquierdo G, Lucas M, Cénit MC, Arroyo R, Vandenbroeck K, Alloza I, García-Barcina M, Antigüedad A, Leyva L, Gómez CL, Olascoaga J, Otaegui D, Blanco Y, Saiz A, Montalbán X, Matesanz F, Urcelay E.

Genes Immun. 2011 Mar;12(2):110-5. doi: 10.1038/gene.2010.52. Epub 2010 Oct 14.

PMID:
20944657
43.

Somatic mosaicism in a case of apparently sporadic Creutzfeldt-Jakob disease carrying a de novo D178N mutation in the PRNP gene.

Alzualde A, Moreno F, Martínez-Lage P, Ferrer I, Gorostidi A, Otaegui D, Blázquez L, Atares B, Cardoso S, Martínez de Pancorbo M, Juste R, Rodríguez-Martínez AB, Indakoetxea B, López de Munain A.

Am J Med Genet B Neuropsychiatr Genet. 2010 Oct 5;153B(7):1283-91. doi: 10.1002/ajmg.b.31099.

PMID:
20872767
44.

Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection.

Vandenbroeck K, Alloza I, Swaminathan B, Antigüedad A, Otaegui D, Olascoaga J, Barcina MG, de las Heras V, Bartolomé M, Fernández-Arquero M, Arroyo R, Alvarez-Lafuente R, Cénit MC, Urcelay E.

Genes Immun. 2011 Jan;12(1):40-5. doi: 10.1038/gene.2010.46. Epub 2010 Sep 23.

PMID:
20861862
45.

Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).

Ruiz-Martínez J, Gorostidi A, Ibañez B, Alzualde A, Otaegui D, Moreno F, López de Munain A, Bergareche A, Gómez-Esteban JC, Martí Massó JF.

Mov Disord. 2010 Oct 30;25(14):2340-5. doi: 10.1002/mds.23278.

PMID:
20721916
46.

The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis.

Alcina A, Vandenbroeck K, Otaegui D, Saiz A, Gonzalez JR, Fernandez O, Cavanillas ML, Cénit MC, Arroyo R, Alloza I, García-Barcina M, Antigüedad A, Leyva L, Izquierdo G, Lucas M, Fedetz M, Pinto-Medel MJ, Olascoaga J, Blanco Y, Comabella M, Montalban X, Urcelay E, Matesanz F.

Genes Immun. 2010 Jul;11(5):439-45. doi: 10.1038/gene.2010.30. Epub 2010 May 27.

PMID:
20508602
47.

Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain.

Swaminathan B, Matesanz F, Cavanillas ML, Alloza I, Otaegui D, Olascoaga J, Cénit MC, de las Heras V, Barcina MG, Arroyo R, Alcina A, Fernandez O, Antigüedad A, Urcelay E, Vandenbroeck K.

J Neuroimmunol. 2010 Jun;223(1-2):100-3. doi: 10.1016/j.jneuroim.2010.03.020. Epub 2010 Apr 28.

PMID:
20430450
48.

Phospholipase Cbeta4 isozyme is expressed in human, rat, and murine heart left ventricles and in HL-1 cardiomyocytes.

Otaegui D, Querejeta R, Arrieta A, Lazkano A, Bidaurrazaga A, Arriandiaga JR, Aldazabal P, Garro MA.

Mol Cell Biochem. 2010 Apr;337(1-2):167-73. doi: 10.1007/s11010-009-0296-x. Epub 2009 Oct 24.

PMID:
19856080
49.

Cognitive/personality pattern and triplet expansion size in adult myotonic dystrophy type 1 (DM1): CTG repeats, cognition and personality in DM1.

Sistiaga A, Urreta I, Jodar M, Cobo AM, Emparanza J, Otaegui D, Poza JJ, Merino JJ, Imaz H, Martí-Massó JF, López de Munain A.

Psychol Med. 2010 Mar;40(3):487-95. doi: 10.1017/S0033291709990602. Epub 2009 Jul 23.

PMID:
19627641
50.

Differential micro RNA expression in PBMC from multiple sclerosis patients.

Otaegui D, Baranzini SE, Armañanzas R, Calvo B, Muñoz-Culla M, Khankhanian P, Inza I, Lozano JA, Castillo-Triviño T, Asensio A, Olaskoaga J, López de Munain A.

PLoS One. 2009 Jul 20;4(7):e6309. doi: 10.1371/journal.pone.0006309.

Supplemental Content

Loading ...
Support Center